Project Grant R01CA297080
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- The National Cancer Institute awarded a $2,489,032 Project Grant to the Sloan-Kettering Institute for Cancer Research on August 1, 2025 under the Cancer Biology Research program (CFDA 93.396). The grant will fund a 5-year research program to investigate the role of lipid metabolism in ferroptosis, a novel cell death process, and explore innovative therapeutic approaches for treating aggressive, drug-resistant cancers. The program consists of three highly integrated projects led by researchers at...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- The Sloan-Kettering Institute for Cancer Research was awarded a $923,999 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the effects of tobacco smoking on African American patients with lung cancer. The award will support a multi-year research initiative from July 1, 2024 to June 30, 2027. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute for...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,194,586 project grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The grant, awarded on September 30, 2023, will support a 3-year research project titled "COEVOLUTION OF METABOLISM AND IMMUNE MICROENVIRONMENT AS A DRIVER OF THERAPEUTIC RESPONSE AND METASTASIS IN CCRCC". Through this grant, the Sloan-Kettering Institute...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $923,805.00 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on "Systematic Functional Dissection of Cancer Cell States in Lung Tumors." The award period runs from Sep 1, 2025 through Aug 31, 2028. The research aims to transform healthcare for military service members, veterans, and the general public by...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
The National Cancer Institute (NCI) awarded a $3,111,184 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the oncogenic mechanisms of the NPM1::TYK2 gene fusion and its role in driving the development of mature T-cell lymphomas, specifically anaplastic large cell lymphoma (ALCL). The project aims to advance the understanding of how this genetic alteration promotes lymphomagenesis and identify downstream signaling pathways that could serve as potential therapeutic targets. The grant award period is from September 1, 2025 to August 31, 2029. As a leading cancer research institution, the Sloan-Kettering Institute has an extensive track record of conducting cutting-edge scientific investigations and delivering critical research services to federal agencies like the NCI.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.1m | 8/28/25 |